Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation

Monica Verdoia; Chiara Sartori; Patrizia Pergolini; Matteo Nardin; Roberta ROLLA; Lucia Barbieri; Alon Schaffer; Paolo MARINO; Giorgio BELLOMO; Harry Suryapranata; GIUSEPPE DE LUCA

doi:10.1016/j.vph.2015.04.014

Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation

Monica Verdoia
, Chiara Sartori
, Patrizia Pergolini
, Matteo Nardin
, Roberta ROLLA
, Lucia Barbieri
, Alon Schaffer
, Paolo MARINO
, Giorgio BELLOMO
, Harry Suryapranata
, GIUSEPPE DE LUCA

Dipartimento di Scienze della Salute

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Residual high-on treatment platelet reactivity (HRPR) predicts outcomes and major cardiovascular events. Ticagrelor has provided pharmacological and clinical evidence of more predictable and more potent antiplatelet effect as compared to clopidogrel. However, so far, few data have investigated the prevalence and predictors of HRPR in unselected patients treated with ticagrelor, that is therefore the aim of the current study.

Lingua originale	Inglese
Rivista	Vascular Pharmacology
Volume	Epub ahead of print
DOI	https://doi.org/10.1016/j.vph.2015.04.014
Stato di pubblicazione	Pubblicato - 2016

Keywords

Acute coronary syndrome
Pharmacological
Platelet aggregation inhibitors
Platelet function tests
Ticagrelor

Accesso al documento

10.1016/j.vph.2015.04.014

http://hdl.handle.net/11579/69986

Altri file e collegamenti

handle

Cita questo

Verdoia, M., Sartori, C., Pergolini, P., Nardin, M., ROLLA, R., Barbieri, L., Schaffer, A., MARINO, P., BELLOMO, G., Suryapranata, H., & DE LUCA, GIUSEPPE. (2016). Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vascular Pharmacology, Epub ahead of print. https://doi.org/10.1016/j.vph.2015.04.014

@article{913bbdeaeca04aad9d57454a7b788b50,

title = "Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation",

abstract = "Residual high-on treatment platelet reactivity (HRPR) predicts outcomes and major cardiovascular events. Ticagrelor has provided pharmacological and clinical evidence of more predictable and more potent antiplatelet effect as compared to clopidogrel. However, so far, few data have investigated the prevalence and predictors of HRPR in unselected patients treated with ticagrelor, that is therefore the aim of the current study.",

keywords = "Acute coronary syndrome, Pharmacological, Platelet aggregation inhibitors, Platelet function tests, Ticagrelor, Acute coronary syndrome, Pharmacological, Platelet aggregation inhibitors, Platelet function tests, Ticagrelor",

author = "Monica Verdoia and Chiara Sartori and Patrizia Pergolini and Matteo Nardin and Roberta ROLLA and Lucia Barbieri and Alon Schaffer and Paolo MARINO and Giorgio BELLOMO and Harry Suryapranata and \{DE LUCA\}, GIUSEPPE",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2016",

doi = "10.1016/j.vph.2015.04.014",

language = "English",

volume = "Epub ahead of print",

journal = "Vascular Pharmacology",

issn = "1537-1891",

publisher = "Elsevier Inc.",

}

Verdoia, M, Sartori, C, Pergolini, P, Nardin, M, ROLLA, R, Barbieri, L, Schaffer, A, MARINO, P, BELLOMO, G, Suryapranata, H & DE LUCA, GIUSEPPE 2016, 'Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation', Vascular Pharmacology, vol. Epub ahead of print. https://doi.org/10.1016/j.vph.2015.04.014

TY - JOUR

T1 - Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation

AU - Verdoia, Monica

AU - Sartori, Chiara

AU - Pergolini, Patrizia

AU - Nardin, Matteo

AU - ROLLA, Roberta

AU - Barbieri, Lucia

AU - Schaffer, Alon

AU - MARINO, Paolo

AU - BELLOMO, Giorgio

AU - Suryapranata, Harry

AU - DE LUCA, GIUSEPPE

PY - 2016

Y1 - 2016

N2 - Residual high-on treatment platelet reactivity (HRPR) predicts outcomes and major cardiovascular events. Ticagrelor has provided pharmacological and clinical evidence of more predictable and more potent antiplatelet effect as compared to clopidogrel. However, so far, few data have investigated the prevalence and predictors of HRPR in unselected patients treated with ticagrelor, that is therefore the aim of the current study.

AB - Residual high-on treatment platelet reactivity (HRPR) predicts outcomes and major cardiovascular events. Ticagrelor has provided pharmacological and clinical evidence of more predictable and more potent antiplatelet effect as compared to clopidogrel. However, so far, few data have investigated the prevalence and predictors of HRPR in unselected patients treated with ticagrelor, that is therefore the aim of the current study.

KW - Acute coronary syndrome

KW - Pharmacological

KW - Platelet aggregation inhibitors

KW - Platelet function tests

KW - Ticagrelor

KW - Acute coronary syndrome

KW - Pharmacological

KW - Platelet aggregation inhibitors

KW - Platelet function tests

KW - Ticagrelor

UR - https://iris.uniupo.it/handle/11579/69986

U2 - 10.1016/j.vph.2015.04.014

DO - 10.1016/j.vph.2015.04.014

M3 - Article

SN - 1537-1891

VL - Epub ahead of print

JO - Vascular Pharmacology

JF - Vascular Pharmacology

ER -

Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo